NCT07587775Enrolling by invitationPhase 2

The Effect of Osteoporotic Medications on Vertebral Bone Quality Score

Source: ClinicalTrials.gov · Last updated 23 Jul 2026

Brief summary (registry, in English)

The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question\[s\] it aims to answer is: Does abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)? Participants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.

Status (registry): Enrolling by invitation
Phase (registry): Phase 2
Study type: Interventional
Enrollment: 60 (estimated)
First submitted: 2 Apr 2026
Start date: 18 Jun 2026
Primary completion date: 1 Jun 2028
Lead sponsor: State University of New York at Buffalo
Diseases: Osteoporosis
NCT number: NCT07587775

What you commit to

Study type: Interventional · Phase 2
Planned participants: 60
From 18 Jun 2026 to the primary completion date, 1 Jun 2028
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Previous lumbar surgery
History of prior treatment with TPTD and ABL

Lab values

Past medical history of: sarcoma, including osteosarcoma, paget disease or other skeletal malignancies, unexplained elevations of alkaline phosphatase, prior external beam radiation, and pre-existing hypercalcemia

Other

Diagnosis of secondary osteoporosis
Vitamin D deficit

Who the study is looking for

Diagnosis of Osteoporosis based on the following criteria:
- Fragility fracture (low trauma fracture similar to a fall from a standing position except for fracture to the skull, face, fingers, and toes)
- T score \<-2.5
- T-score -1 to -2.5 with a high FRAX or high TBS adjusted FRAX (with a 10-year probability of major osteoporotic fracture ≥20% or a 10-year probability of hip fracture ≥3%)
Fulfill criteria for treatment with anabolic therapy, as outlined in the American Association of Clinical Endocrinologist guidelines for the diagnosis and treatment of postmenopausal osteoporosis in women and Evidence-Based Guideline for the management of osteoporosis in men.
Lumbar Degenerative Disease as evidenced by a diagnosis of spondylosis, spondylolisthesis, degenerative disc disease with spinal stenosis, and degenerative scoliosis
Have or be willing to have a DEXA scan, lumbar MRI, and lumbar CT within 3 months of the start of Abaloparatide
If on thyroid hormone replacement, having been on it for at least 6 months

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
University at Buffalo Neurosurgery Coordinator of this site? Confirm its status	Buffalo	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.